CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 53 enrolled
Drug / intervention
Biologic wound graftdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03232333
NCT03232333N/ACompleted
CompareCT.gov

Effectiveness of MIRODERM® Biologic Wound Matrix in the Treatment of Hard-to-Heal Diabetic Foot Ulcers

Miromatrix Medical Inc.·observational·Posted Jul 28, 2017·Updated Oct 22, 2019

In Brief

An observational study evaluating Biologic wound graft for Diabetic Foot Ulcer. Completed, enrolled 53 participants across 9 sites.

Detailed Summary

This study will assess the ability of MIRODERM to heal difficult diabetic foot ulcers within 12 weeks of treatment.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Foot Ulcer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedJul 28, 2017
Enrollment StartJul 21, 2017
Primary CompletionSep 20, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.9 years ago

Interventions

Biologic wound graftdevice

Diabetic foot ulcer will be treated by grafting with MIRODERM Biologic Wound Matrix